Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)

peer reviewedThe authors regret that at the time the article was published, Supplementary Table S2 contained errors. This has now been corrected. The authors would like to apologise for any inconvenience caused

Electrochemically synthesized polymers in molecular imprinting for chemical sensing

This critical review describes a class of polymers prepared by electrochemical polymerization that employs the concept of molecular imprinting for chemical sensing. The principal focus is on both conducting and nonconducting polymers prepared by electropolymerization of electroactive functional monomers, such as pristine and derivatized pyrrole, aminophenylboronic acid, thiophene, porphyrin, aniline, phenylenediamine, phenol, and thiophenol. A critical evaluation of the literature on electrosynthesized molecularly imprinted polymers (MIPs) applied as recognition elements of chemical sensors is presented. The aim of this review is to highlight recent achievements in analytical applications of these MIPs, including present strategies of determination of different analytes as well as identification and solutions for problems encountered

Distribution Of Sickle Cell Gene in Korku Tribe of Central India

Background: The intension of the study was not only to reveal current prevalence rate of sickle cell disease (SCD) but also to adduce most probable reason for its high prevalence in Korku population of Central India and its implications on their health. Methods: During the study, a total of 865 subjects belonging to different age groups (0-60 years) were randomly sampled for estimating the incidence of sickle cell genotype in them. Blood samples were collected from all (n=865) individuals and positive samples were subjected to cellulose acetate Hb electrophoresis at pH 8.6 for confirmation of their patterns. Prepared questionnaire and previous medical reports were used as a tool to diagnose the clinical presentations of SCD. Result: Prevalence of sickle cell trait among Korku people was found to be 5.3% (46/865), of which 4.4% with heterozygous gene AS (Carrier) whereas 0.9% with homozygous recessive gene SS (Disease). The frequency of SCD gene was reported more in males and in lower age groups especially in people belonging to the age group of 0-25 years. In homozygous individuals 87.8% of them had no history of pain crisis or blood transfusion. In heterozygous patients most frequently observed clinical features were body pain, joint pain, fever, abdominal pain, pallor and limited complaints about chest pain and intermittent jaundice. No complaint of gall stone was reported. The data also reflects high rate of mortality especially in children. Conclusion: The high degree of consanguinity and lack of knowledge about sickle cell disorder are major reasons for high SCD gene frequency amongst Korku tribesmen. Premarital screening and genetic counseling needs to be considered as tools to reduce its rate of prevalence

Synthesis and Characterization of Pure and Al Modified BaSnO3 Thick Film Resistor and Studies of its Gas Sensing Performance

In this work we report the synthesis, microstructure, electric properties and sensing performance of BaSnO3 (BS) powder, it was prepared by solid state mechano-chemical method. As prepared powder is calcinated at temperatures 1000 °C and 1200 °C and tested for crystallization. Thick films were prepared using simple yet effective screen-printing technology. Structural and electrical analyses were performed and the results have been correlated. The pure BS film shows good response (S=9.8) to NH3 at elevated temperature up to 500 °C along with response other gases with lower sensitivity such as CO2, CO, H2S for various gas concentrations, when the pure film is surface modified with Al2O3, film improves the selectivity and sensitivity. Maximum response (S=21.2) was found to H2S gas at temperature of 300 °C for gas concentration as low as up to 100 ppm. The characterization of the films was done by XRD, SEM and TGA. Crystallite size, surface area, electric properties and gas sensitivity of the films were measured and presented

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Y Background: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). Here we present a new landmark in survival follow-up for a phase III cyclin-dependent kinases 4 and 6 inhibitor clinical trial in patients with ABC (median, 56.3 months). Patients and methods: This phase III, randomized, double-blind, placebo-controlled trial was conducted at 174 sites (30 countries). Patients were men and postmenopausal women (age >18 years) with histologically/cytologically confirmed HR+/HER2- ABC. Patients could have received 1 dose study treatment. OS was a secondary endpoint. MONALEESA-3 is registered with ClinicalTrials.gov (NCT02422615; no longer enrolling). Results: Between 18 June 2015 and 10 June 2016, 726 patients were randomly assigned (484, ribociclib; 242, placebo). At data cut-off (30 October 2020), median OS (mOS) was 53.7 months (ribociclib) versus 41.5 months (placebo) [hazard ratio (HR), 0.73; 95% confidence interval (CI) 0.59-0.90]. Subgroup analyses were consistent with overall population. In the first-line setting, most patients in the ribociclib arm (similar to 60%) lived longer than median follow-up; mOS was 51.8 months in the placebo arm (HR, 0.64; 95% CI 0.46-0.88). In the second-line setting, mOS was 39.7 months (ribociclib) versus 33.7 months (placebo) (HR, 0.78; 95% CI 0.59-1.04). No apparent drugedrug interaction between ribociclib and fulvestrant or new safety signals were observed. Conclusions: This analysis reported extended OS follow-up in MONALEESA-3. mOS was similar to 12 months longer in patients with HR+/HER2- ABC treated with ribociclib plus fulvestrant compared with fulvestrant monotherapy

Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)

status: publishe

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.

peer reviewedBACKGROUND: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). Here we present a new landmark in survival follow-up for a phase III cyclin-dependent kinases 4 and 6 inhibitor clinical trial in patients with ABC (median, 56.3 months). PATIENTS AND METHODS: This phase III, randomized, double-blind, placebo-controlled trial was conducted at 174 sites (30 countries). Patients were men and postmenopausal women (age ≥18 years) with histologically/cytologically confirmed HR+/HER2- ABC. Patients could have received ≤1 line of endocrine therapy (ET) but no chemotherapy for ABC. Patients, assigned 2:1, were stratified by the presence/absence of liver/lung metastases and previous ET. Patients received intramuscular fulvestrant (500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1) with oral ribociclib (600 mg/day, 3 weeks on, 1 week off) or placebo. Efficacy analyses were by intention to treat. Safety was assessed in patients receiving ≥1 dose study treatment. OS was a secondary endpoint. MONALEESA-3 is registered with ClinicalTrials.gov (NCT02422615; no longer enrolling). RESULTS: Between 18 June 2015 and 10 June 2016, 726 patients were randomly assigned (484, ribociclib; 242, placebo). At data cut-off (30 October 2020), median OS (mOS) was 53.7 months (ribociclib) versus 41.5 months (placebo) [hazard ratio (HR), 0.73; 95% confidence interval (CI) 0.59-0.90]. Subgroup analyses were consistent with overall population. In the first-line setting, most patients in the ribociclib arm (∼60%) lived longer than median follow-up; mOS was 51.8 months in the placebo arm (HR, 0.64; 95% CI 0.46-0.88). In the second-line setting, mOS was 39.7 months (ribociclib) versus 33.7 months (placebo) (HR, 0.78; 95% CI 0.59-1.04). No apparent drug-drug interaction between ribociclib and fulvestrant or new safety signals were observed. CONCLUSIONS: This analysis reported extended OS follow-up in MONALEESA-3. mOS was ∼12 months longer in patients with HR+/HER2- ABC treated with ribociclib plus fulvestrant compared with fulvestrant monotherapy